This COVID-Era Biotech Favorite Is Surging Once Again On Strong Q4 Guidance: Momentum Score Spikes - Moderna (NASDAQ:MRNA)

Core Viewpoint - Moderna Inc. is experiencing a resurgence in stock momentum after a significant decline since its peak in 2021, driven by improved financial outlook and investor sentiment [1][4]. Group 1: Stock Performance - The stock has seen a 91.87% decline from its all-time high in 2021, but has recently gained 76% from its November 2025 lows [1][3]. - The Momentum score in Benzinga's Edge Stock Rankings has increased from 22.5 to 74.61 in just one week, indicating a strong turnaround in investor sentiment [2][3]. - Shares have climbed 31.7% in the past month and an additional 14.8% over the past week [3]. Group 2: Financial Outlook - Moderna's full-year 2025 revenue is projected at $1.9 billion, exceeding previous estimates by approximately $100 million [4]. - The company has reduced its GAAP operating expense forecast by about $200 million for the year, improving its cost structure [4]. - The projected year-end cash balance has been increased to $8.1 billion, contributing to positive investor sentiment [4]. Group 3: Recent Trading Activity - On a recent trading day, shares of Moderna closed down 3.01% at $39.36 but were up 0.66% overnight [5]. - The stock maintains a favorable price trend across short, medium, and long-term time frames in Benzinga's Edge Stock Rankings [5].